MD2336G2 - Кристаллический гидрат 6-гидрокси-3-(4-[2-(пиперидин-1-ил) этокси]фенокси)-2-(4-метоксифенил)бензо[b]тиофен гидрохлорида, способ получения, фармацевтическая композиция его содержащая и применение для ингибирования паталогических состояний и активирования холинацетилтрансферазы - Google Patents
Кристаллический гидрат 6-гидрокси-3-(4-[2-(пиперидин-1-ил) этокси]фенокси)-2-(4-метоксифенил)бензо[b]тиофен гидрохлорида, способ получения, фармацевтическая композиция его содержащая и применение для ингибирования паталогических состояний и активирования холинацетилтрансферазыInfo
- Publication number
- MD2336G2 MD2336G2 MDA20000162A MD20000162A MD2336G2 MD 2336 G2 MD2336 G2 MD 2336G2 MD A20000162 A MDA20000162 A MD A20000162A MD 20000162 A MD20000162 A MD 20000162A MD 2336 G2 MD2336 G2 MD 2336G2
- Authority
- MD
- Moldova
- Prior art keywords
- benzo
- piperidine
- phenoxy
- ethoxy
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/64—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Изобретение относится к фармацевтической технологии, в частности к новой кристаллической форме 6-гидрокси-3-(4-[2-(пиперидин-1-ил) этокси]фенокси)-2-(4-метоксифенил)бензо[b]тиофен гидрохлорида, способу получения и композиции его содержащей.Кристаллический гидрат 6-гидрокси-3-(4-[2-(пиперидин-1-ил) этокси]фенокси)-2-(4-метоксифенил)бензо[b]тиофен гидрохлорида (арзофен), F-1, представляет собой вещество с высокой степенью кристаллизации. Фармацевтическая композиция на его основе содержит один или больше носителей, растворители или заменители и при необходимости эстроген, прогестин, ингибитор ароматазы, аналог гормона, который освобождает лютеинизирующий гормон (LHRH) и ингибитор ацетилхолинэстэразы. Способ получения упомянутого вещества предусматривает кристаллизацию 6-гидрокси-3-(4-[2-(пиперидин-1-ил)этокси]фенокси)-2-(4-метоксифенил)бензо[b]тиофен гидрохлорида из тетрагидрофурана.Заявленное соединение можно использовать для ингибирования патологических состояний, связанных с дефицитом эстрогена, таких, как фиброз матки, эндометриоз, пролиферацию гладких мышечных клеток в аорте, рестеноз, эстроген-зависимый рак (включая рак молочной железы и рак матки), рак простаты, доброкачественная гиперплазия простаты, остеопороз, сердечно-сосудистые заболевания, гиперлипидемия, расстройства ЦНС и болезнь Альцгеймера, предупреждения рака молочной железы и активирования холинацетилтрансферазы.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14628699P | 1999-07-29 | 1999-07-29 | |
US14757099P | 1999-08-06 | 1999-08-06 | |
US14977399P | 1999-08-19 | 1999-08-19 |
Publications (3)
Publication Number | Publication Date |
---|---|
MD20000162A MD20000162A (en) | 2001-04-30 |
MD2336F2 MD2336F2 (en) | 2003-12-31 |
MD2336G2 true MD2336G2 (ru) | 2004-06-30 |
Family
ID=27386379
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MDA20000162A MD2336G2 (ru) | 1999-07-29 | 2000-07-28 | Кристаллический гидрат 6-гидрокси-3-(4-[2-(пиперидин-1-ил) этокси]фенокси)-2-(4-метоксифенил)бензо[b]тиофен гидрохлорида, способ получения, фармацевтическая композиция его содержащая и применение для ингибирования паталогических состояний и активирования холинацетилтрансферазы |
Country Status (45)
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE251151T1 (de) * | 1999-07-29 | 2003-10-15 | Lilly Co Eli | Eine kristalline form von 6-hydroxy-3-(4-(2- (piperidin-1-yl)ethoxy)phenoxy)-2-(4- methoxyphenyl)benzo(b)thiophen-hydrochlorid |
US7122203B2 (en) | 2000-05-08 | 2006-10-17 | Eli Lilly And Company | Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof |
DE60125416T2 (de) * | 2000-05-08 | 2007-09-27 | Eli Lilly And Co., Indianapolis | Stabilisierte formulierungen von 6-hydroxy-3-(4-(2-(piperidin-1-yl)ethoxy)phenoxy)-2-(4-methoxyphenyl)benzo(b)thiophen und deren salze |
EP1757291A3 (en) * | 2000-05-08 | 2009-07-15 | Eli Lilly & Company | Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof |
EP1157996A1 (de) * | 2000-05-23 | 2001-11-28 | JENAPHARM GmbH | Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on |
IL155487A0 (en) * | 2000-10-20 | 2003-11-23 | Lilly Co Eli | A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2- (PIPERIDIN-1-YL) ETHOXY] PHENOXY)-2-(4-METHOXYPHENYL) BENZO[b]THIOPHENE HYDROCHLORIDE |
WO2002042289A2 (en) | 2000-11-27 | 2002-05-30 | Eli Lilly And Company | Process for preparing 3-aryl-benzo[b]thiophenes |
CA2393720C (en) * | 2002-07-12 | 2010-09-14 | Eli Lilly And Company | Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride |
EP1773811B1 (en) * | 2004-07-22 | 2010-09-08 | Eli Lilly And Company | A crystalline variable hydrate of (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinecarbox amide hemisuccinate salt |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5510357A (en) * | 1995-02-28 | 1996-04-23 | Eli Lilly And Company | Benzothiophene compounds as anti-estrogenic agents |
EP0729956A1 (en) * | 1995-02-28 | 1996-09-04 | Eli Lilly And Company | Benzothiophene compounds, intermediates, compositions, and methods |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA9710262B (en) * | 1996-11-19 | 1999-05-13 | Lilly Co Eli | Process for the synthesis of benzothiophenes |
ZA982877B (en) * | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment of central nervous system disorders with selective estrogen receptor modulators. |
-
2000
- 2000-07-17 WO PCT/US2000/016333 patent/WO2001009116A2/en not_active Application Discontinuation
- 2000-07-17 EP EP00950223A patent/EP1204656A2/en not_active Ceased
- 2000-07-17 AU AU63356/00A patent/AU6335600A/en not_active Abandoned
- 2000-07-18 LV LVP-00-94A patent/LV12623B/en unknown
- 2000-07-21 RO ROA200000736A patent/RO121851B1/ro unknown
- 2000-07-24 ID IDP20000629D patent/ID27078A/id unknown
- 2000-07-24 CZ CZ20002716A patent/CZ299311B6/cs not_active IP Right Cessation
- 2000-07-25 HR HR20000503A patent/HRP20000503B1/xx not_active IP Right Cessation
- 2000-07-27 CO CO00056521A patent/CO5180570A1/es active IP Right Grant
- 2000-07-27 TR TR2000/02206A patent/TR200002206A2/xx unknown
- 2000-07-27 IL IL13755300A patent/IL137553A/xx not_active IP Right Cessation
- 2000-07-27 NL NL1015821A patent/NL1015821C2/nl not_active IP Right Cessation
- 2000-07-28 UA UA2000074563A patent/UA72885C2/ru unknown
- 2000-07-28 SG SG200004288A patent/SG91296A1/en unknown
- 2000-07-28 NO NO20003879A patent/NO20003879L/no not_active Application Discontinuation
- 2000-07-28 AT AT0132400A patent/AT502318A1/de not_active Application Discontinuation
- 2000-07-28 SV SV2000000132A patent/SV2002000132A/es unknown
- 2000-07-28 TW TW089115154A patent/TWI276437B/zh not_active IP Right Cessation
- 2000-07-28 PT PT102502A patent/PT102502A/pt not_active IP Right Cessation
- 2000-07-28 SE SE0002792A patent/SE0002792L/xx unknown
- 2000-07-28 KR KR1020000043651A patent/KR100697177B1/ko not_active IP Right Cessation
- 2000-07-28 JP JP2000228939A patent/JP2001064277A/ja active Pending
- 2000-07-28 MY MYPI20003453A patent/MY128764A/en unknown
- 2000-07-28 FR FR0009969A patent/FR2796944B1/fr not_active Expired - Fee Related
- 2000-07-28 BE BE2000/0478A patent/BE1013411A3/fr not_active IP Right Cessation
- 2000-07-28 BR BR0003209-3A patent/BR0003209A/pt not_active Application Discontinuation
- 2000-07-28 LT LT2000076A patent/LT4790B/lt not_active IP Right Cessation
- 2000-07-28 AR ARP000103928A patent/AR031073A1/es unknown
- 2000-07-28 MX MXPA00007461A patent/MXPA00007461A/es active IP Right Grant
- 2000-07-28 MD MDA20000162A patent/MD2336G2/ru not_active IP Right Cessation
- 2000-07-28 PL PL00341749A patent/PL341749A1/xx not_active Application Discontinuation
- 2000-07-28 HU HU0003001A patent/HUP0003001A2/hu unknown
- 2000-07-28 CA CA002314682A patent/CA2314682A1/en not_active Abandoned
- 2000-07-28 FI FI20001722A patent/FI20001722A/fi unknown
- 2000-07-28 LU LU90617A patent/LU90617B1/fr active
- 2000-07-28 IT IT2000MI001759A patent/IT1318660B1/it active
- 2000-07-28 DE DE10036854A patent/DE10036854A1/de not_active Withdrawn
- 2000-07-28 GB GB0018641A patent/GB2352717A/en not_active Withdrawn
- 2000-07-28 CN CNB001222376A patent/CN1138770C/zh not_active Expired - Fee Related
- 2000-07-28 DK DK200001151A patent/DK200001151A/da not_active Application Discontinuation
- 2000-07-28 SI SI200000172A patent/SI20426A/sl not_active IP Right Cessation
- 2000-07-28 GR GR20000100265A patent/GR1004084B/el unknown
- 2000-07-29 DZ DZ000126A patent/DZ3060A1/xx active
- 2000-07-31 PE PE2000000757A patent/PE20010385A1/es not_active Application Discontinuation
-
2001
- 2001-09-03 HK HK01106204A patent/HK1035370A1/xx not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5510357A (en) * | 1995-02-28 | 1996-04-23 | Eli Lilly And Company | Benzothiophene compounds as anti-estrogenic agents |
EP0729956A1 (en) * | 1995-02-28 | 1996-09-04 | Eli Lilly And Company | Benzothiophene compounds, intermediates, compositions, and methods |
US5723474A (en) * | 1995-02-28 | 1998-03-03 | Eli Lilly And Company | Benzothiophene compounds, intermediates, compositions, and methods |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MD2336G2 (ru) | Кристаллический гидрат 6-гидрокси-3-(4-[2-(пиперидин-1-ил) этокси]фенокси)-2-(4-метоксифенил)бензо[b]тиофен гидрохлорида, способ получения, фармацевтическая композиция его содержащая и применение для ингибирования паталогических состояний и активирования холинацетилтрансферазы | |
MD2335G2 (ru) | Кристаллический гидрат 6-гидрокси-3-(4-[2-(пиперидин-1-ил)этокси]фенокси)-2-(4-метоксифенил)бензо[b]тиофен гидрохлорида, способ получения, фармацевтическая композиция его содержащая и применение для ингибирования патологических состояний и активирования холинацетилтрансферазы | |
AU1296902A (en) | Isoquinolinone potassium channel inhibitors | |
NO944876L (no) | Sammensetning for behandling av menstruelle symptomer | |
PL373903A1 (en) | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease | |
EE9800173A (et) | Gonadotropiini riliisinghormooni antagonistid | |
CA2228997A1 (en) | Benzothiophene compounds | |
ATE248832T1 (de) | Antagonisten des gonadotropin freisetzenden hormons | |
WO2002034741A3 (en) | A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE | |
RU2000120574A (ru) | НОВАЯ КРИСТАЛЛИЧЕСКАЯ ФОРМА 6-ГИДРОКСИ-3-(4-[2-(ПИПЕРИДИН-1-ИЛ)ЭТОКСИ]ФЕНОКСИ)-2-(4-МЕТОКСИФЕНИЛ)БЕНЗ[b]ТИОФЕНА ГИДРОХЛОРИДА | |
RU2000120575A (ru) | НОВАЯ КРИСТАЛЛИЧЕСКАЯ ФОРМА 6-ГИДРОКСИ-3-(4-[2-(ПИПЕРИДИН-1-ИЛ)ЭТОКСИ]ФЕНОКСИ)-2-(4-МЕТОКСИФЕНИЛ)БЕНЗ[b]ТИОФЕНА ГИДРОХЛОРИДА | |
TH55348B (th) | รูปผลึกแบบใหม่ของ 6-ไฮดรอกซี-3-(4-[2-พิเพอริดิน-1-อิล) เอทอกซี] ฟีนอกซี)-2-(4-เมทอกซีเฟนิล)เบนโซ[3] ไทโอฟีนไฮโดรดคลอไรด์ | |
CA2359958A1 (en) | Process for preparing 1-(6-methylpyridin-3yl)-2-[(4-methylsulfonyl)phenyl]ethanone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KA4A | Patent for invention lapsed due to non-payment of fees (with right of restoration) | ||
MM4A | Patent for invention definitely lapsed due to non-payment of fees |